Project description
Cholera, caused by the bacterium Vibrio cholerae, remains a significant public health challenge in low-resource settings, particularly in sub-Saharan Africa. Despite efforts to control the disease, cholera outbreaks continue to occur, with Kenya experiencing several significant epidemics in recent years. Oral cholera vaccines (OCVs) are a critical tool in cholera prevention strategies. Therefore, this study aims to evaluate the immunogenicity of extended dosing intervals for Euvichol-S, a WHO-prequalified OCV, in a Phase IV non-inferiority trial.
This trial is a parallel-group, open-label, randomized, non-inferiority study. It aims to compare the immune response of three dosing schedules of the Euvichol-S OCV: a standard two-week interval, a three-month interval, and a twelve-month interval.
The project has opportunities for the following positions:
Terms of employment: This is a one (1) year contract, renewable subject to availability of funds, with a probation period for the first 3 months. Salary is negotiable within the KEMRI scheme of service depending on education, experience and demonstrated competency.
Successful candidates will be required to provide the following: Certificate of good conduct, Higher Education Loans Board compliance certificate, KRA Tax compliance certificate, Ethics and Anti-Corruption Commission clearance.
Kindly attach your CV, cover letter, copies of certified academic and professional certificates, testimonials and other relevant documents
.All the applications to be done through KEMRI Website www.kemri.go.ke/e- recruitment – E-Recruitment Portal on or before 11th September, 2024, 5.00 p.m.
Please visit the KEMRI web site www.kemri.go.ke for more details on the advertisement.
Only Short listed candidates will be contacted.